Dynamic Contrast-Enhanced Perfusion MR Imaging With SPIO A Pilot Study
Dynamic Contrast-Enhanced Perfusion MR Imaging With SPIO A Pilot Study
复制标题
DOI：
10.1097/rli.0b013e3181b4c08f
复制
发表时间：
2009-09-01
影响因子：
6.7
通讯作者：
Ohtomo, Kuni
中科院分区：
文献类型：
--
作者：
Amemiya, Shiori;Akahane, Masaaki;Ohtomo, Kuni
目的：探讨3.0T铁硫脲动态磁化率加权对比剂增强(DSC)脑血流灌注成像的可行性，以及在血脑屏障破坏的病理条件下，不同性质的Gd和铁硫脲试剂对rCBV测量的影响。材料与方法：9例疑似脑膜瘤患者，男4例，女5例；年龄27~79岁，平均年龄61.6±17.9岁。获得了机构审查委员会的批准。所有参与者在研究前都提供了签署的知情同意书。DSC灌注成像采用T2加权回波平面成像序列，分别在标准剂量的Gd基试剂和4、8或16mU摩尔Fe/kg剂量的3例患者的每个剂量下采集。结果：Feucarbotran可剂量依赖性地降低灰质和白质的信号强度。在任何地区，4和8或8和16 mU摩尔铁/公斤组之间的Delta SI差异均有统计学意义(P<；0.05，单因素方差分析，Tukey-Kramer法)。在强度-时间曲线或增强后的T1加权图像中，未显示亚铁氰尿嘧啶泄漏的影响。结论：在3.0T条件下，含铁碳盘的T2加权DSC灌注成像是可行的，与Gd相比，较大的铁碳盘颗粒可以减少在有血脑屏障破坏的病理条件下第一次通过时的对比剂渗漏的影响。
Purpose: To investigate the feasibility of dynamic susceptibility-weighted contrast material-enhanced (DSC) perfusion imaging with ferucarbotran at 3.0 T, and to assess the impact of the different characteristics of gadolinium (Gd)- and ferucarbotran-based agent in rCBV measurement under pathologic condition with BBB disruption.Materials and Methods: Nine patients with suspected meningioma (4 men and 5 women; age range, 27-79 years; mean age, 61.6 +/- 17.9 years) were eligible for the study. Approval was obtained from the institutional review board. All participants provided signed informed consent prior to the study. DSC perfusion images were acquired with a T2*-weighted echo-planar imaging sequence during the first pass of a standard-dose of Gd-based agent, and of 4, 8, or 16 mu mol Fe/kg of ferucarbotran-based agent in 3 patients for each dose respectively. Pre- and postenhanced T1-weighted images were obtained in all.Results: Ferucarbotran decreased the signal intensity in both gray and white matter in a dose-dependent fashion. Differences regarding the Delta SI between the 4 and 8 or 8 and 16 mu mol Fe/kg groups were statistically significant (P < 0.05, 1-way analysis of variance, Tukey-Kramer method) in any region. No effect of leakage of ferucarbotran was demonstrated in the intensity-time curves or in the postenhanced T1-weighted images. Relative CBV in tumor area obtained with Gd was reduced to 37.6%-86.5% compared with that obtained with ferucarbotran.Conclusions: T2*-weighted DSC perfusion imaging with ferucarbotran is feasible at 3.0 T. Compared with Gd-based agent, larger particle size of ferucarbotran can diminish the effect of contrast leakage during the first pass under pathologic conditions with BBB disruption.